Kazia Therapeutics
KZIA
10 hedge funds and large institutions have $903K invested in Kazia Therapeutics in 2025 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 2 closing their positions.
3,838% more capital inflows, than outflows
Capital inflows: $542K | Capital outflows: $13.8K
7.83% more ownership
Funds ownership: 2.76% → 10.59% (+7.8%)
0% more funds holding
Funds holding: 10 → 10 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DIG
Dauntless Investment Group
Etna,
New Hampshire
|
+$541K |
| 2 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$976 |
| 3 |
SBI Securities
Tokyo,
Japan
|
+$467 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$10.4K |
| 2 |
MAI Capital Management
Independence,
Ohio
|
-$3.36K |
| 3 |
Wells Fargo
San Francisco,
California
|
-$3 |
KZIA Hedge Fund Activity: Q2 2025 in Review
10 of the 7,627 institutional investors tracked by Wall St. Rank reported a position in Kazia Therapeutics (KZIA) for Q2 2025, worth a combined $903K — up 647% from $121K a quarter earlier.
Fund positioning in KZIA was balanced in Q2 2025: 2 funds opened new positions, 2 closed out, 1 added to existing stakes and 2 trimmed.
The largest buyer was Dauntless Investment Group, opening a new position worth an estimated $541K. The largest seller was UBS Group, cutting an estimated $10.4K.
- 10 institutional investors held Kazia Therapeutics (KZIA) as of Q2 2025, unchanged from Q1 2025.
- Funds reported $903K of Kazia Therapeutics stock for Q2 2025, up 647% quarter-over-quarter.
- 2 funds opened new Kazia Therapeutics positions in Q2 2025 and 2 closed out, a net change of 0 holders.
- The largest Kazia Therapeutics buyer in Q2 2025 was Dauntless Investment Group, an estimated $541K added.
- The largest Kazia Therapeutics seller in Q2 2025 was UBS Group, an estimated $10.4K sold.
Based on aggregated 13F filings for Q2 2025.